Lane D J
Clin Allergy. 1980 Sep;10(5):519-25. doi: 10.1111/j.1365-2222.1980.tb02132.x.
In a multicentre, double-blind trial, the steroid sparing effect of a new anti-anaphylactic agent ketotifen was assessed against placebo in eighty-six steroid-dependent asthmatics. Mean reduction in total daily prednisolone dosage in patients on ketotifen was 4.0 +/- 3.6 mg compared to 1.7 +/- 2.8 mg on placebo, a result significantly in favour of the active drug (P < 0.01). This suggests that ketotifen has a place similar to that of disodium cromoglycate or steroid aerosols in the managment of steroid-dependent asthmatics. It has the advantage of requiring only twice-daily oral administration.
在一项多中心双盲试验中，对86名依赖类固醇的哮喘患者评估了新型抗过敏药酮替芬相对于安慰剂的类固醇节省效应。服用酮替芬的患者每日泼尼松龙总剂量平均减少4.0±3.6毫克，而服用安慰剂的患者为1.7±2.8毫克，结果明显有利于活性药物（P<0.01）。这表明酮替芬在依赖类固醇哮喘患者的治疗中具有与色甘酸钠或类固醇气雾剂类似的地位。它的优点是只需每日口服两次。
